Impact of CT outcomes on time to market and list price of orphan medicines in France
More innovative medicines have a shorter assessment time by the CT ASMR rating achieved vs. average time from EMA approval to outcome of CT assessment Key...
Industries
Life Sciences
We bring clarity to complex challenges.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
Engagements
- 01AAA dispute in commercially reasonable efforts to market a hospital administered drugCRA expert, Dr. Sean Sheridan considered the Respondent’s efforts as they relate to the obligations of the licensing agreement and evaluated those efforts...View engagement
- 02Expert report, testimony in university vs biopharmaceutical companyDr. Sean Sheridan provided expert testimony on academic technology transfer practices and responded to the Plaintiff’s expert’s opinions regarding certain...View engagement
- 03EC unconditionally approves $16.5bn acquisition of Catalent by Novo HoldingsBy providing additional fill-finish capacity, the transaction would enable Novo Nordisk to reach more obesity and diabetes patients faster. The Commission...View engagement
Contact a Life Sciences expert.
See all Life Sciences expertsUpcoming events
World EPA Congress
CRA is a proud sponsor of the event covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes...
Intellus Worldwide 2025 Summit
CRA is a proud sponsor of the event. Kaitlyn Austin presents the session titled “Securing Insight Alignment to Drive Future-Proofed Strategies and...
Recent events
JP Morgan Panel Discussion - Navigating the New Landscape: What will happen with prices?
It’s been a little over two years since the Inflation Reduction Act (IRA) was enacted. During this period, the first ten products have been negotiated with...
2024 ASHP Midyear Clinical Meeting and Exhibition
This panel will offer economic insights from both Pfizer and non-Pfizer experts, covering the following topics: Identifying economic factors that contribute...